The final step in the solubilization partnership between the companies is expected to aid Dow to commercially supply solubility enabling excipients.
Dow senior R&D director Bob Maughon said, "The AFFINISOL™ product platform has excellent manufacturing flexibility to match the diverse excipients needs of our customers’ pipelines."
The product is scheduled to be commercially available by the end of 2013.
Construction commenced on the new operational facility at Cambrex Karlskoga.
Cambrex sales and business development VP Eric Neuffer said, "This agreement between Dow and Cambrex further validates Cambrex’s commitment to finding solutions that offer our clients quality products and services to meet a market need."